

# ACTIN Report (research use only)

PATIENT  
EXAMPLE-CRC-01  
  
REPORT DATE  
17-Sep-2025

Gender: **Female** | Birth year: **1946** | WHO: **0**

Tumor: **Colorectum (cecum) carcinoma** | Lesions: **Lung, Peritoneal** | Stage: **IV**

## Clinical summary

Relevant systemic treatment history	<b>None</b>	
Relevant other oncological history	11/2021	<b>Hemicolecction right (Cecum)</b>
Previous primary tumor	<b>Skin squamous cell carcinoma (diagnosed 6/2016, last treatment 8/2016, considered non-active)</b>	
Relevant non-oncological history	1/2019	<b>Cerebrovascular accident</b>

## Standard-of-care options considered potentially eligible

Treatment	Literature efficacy evidence	Warnings
<b>FOLFIRI</b>	<a href="#">PHASE-3-CRC</a>  <b>PFS:</b> 10.0 months (95% CI: 10.0-12.0) <b>OS:</b> 25.0 months (95% CI: 25.0-30.0)	

## Phase 2/3+ trials in NL that are open and potentially eligible (0 trials)

None

## Phase 1/2 (or unknown phase) trials in NL that are open and potentially eligible (1 trial)

Trial	Cohort	Molecular	Sites	Warnings
<a href="#"><u>KRAS-G12D-TRIAL</u></a> <i>(Phase 1)</i>	<i>KRAS G12D</i>	<i>KRAS G12D</i>	<i>UMC Utrecht</i>	

Trials matched solely on molecular event and tumor type (no clinical data used) are shown in italicized, smaller font.

## Molecular Details

### NGS & MSI Panel (15-Jan-2023)

Biopsy location	Lung
Tumor mutational burden	TMB 8 mut/Mb
Microsatellite (in)stability	Stable
Driver mutations	KRAS G12D

### IHC results

Ki67	Positive, score 90%
PD-L1	Score < 50%

## Efficacy evidence


### Standard of care options considered potentially eligible

The following standard of care treatment(s) could be an option for this patient. For further details per study see 'SOC literature details' section in extended report.

Treatment	Literature efficacy evidence												
FOLFIRI	<p><a href="#">PHASE-3-CRC</a></p> <p><b>Patient characteristics:</b></p> <table><tbody><tr><td>WHO/ECOG</td><td>0: 100, 1: 80, 2: 20, 3: 0, 4: 0</td></tr><tr><td>Primary tumor location</td><td>Left: 145, Both or unknown: 10, Right: 45</td></tr><tr><td>Mutations</td><td>KRAS exon 2 wild-type 200/200</td></tr><tr><td>Metastatic sites</td><td>Liver only: 58 (32.0%), Lung only: 10 (6.0%)</td></tr><tr><td>Previous systemic therapy</td><td>35/200</td></tr><tr><td>Prior therapies</td><td>Adjuvant chemotherapy</td></tr></tbody></table> <p><b>Median PFS:</b> 10.0 months (95% CI: 10.0-12.0)</p> <p><b>Median OS:</b> 25.0 months (95% CI: 25.0-30.0)</p>	WHO/ECOG	0: 100, 1: 80, 2: 20, 3: 0, 4: 0	Primary tumor location	Left: 145, Both or unknown: 10, Right: 45	Mutations	KRAS exon 2 wild-type 200/200	Metastatic sites	Liver only: 58 (32.0%), Lung only: 10 (6.0%)	Previous systemic therapy	35/200	Prior therapies	Adjuvant chemotherapy
WHO/ECOG	0: 100, 1: 80, 2: 20, 3: 0, 4: 0												
Primary tumor location	Left: 145, Both or unknown: 10, Right: 45												
Mutations	KRAS exon 2 wild-type 200/200												
Metastatic sites	Liver only: 58 (32.0%), Lung only: 10 (6.0%)												
Previous systemic therapy	35/200												
Prior therapies	Adjuvant chemotherapy												


# ACTIN Report (research use only)

PATIENT  
EXAMPLE-CRC-01  
  
REPORT DATE  
17-Sep-2025





All results and data described in this report are for Research Use Only and have NOT been generated using a clinically validated and controlled procedure nor is it a validated medical device. The results should NOT be used for diagnostic or treatment purposes. No rights can be derived from the content of this report.

## SHAP values for treatment: No Treatment



## SHAP values for treatment: FOLFIRI





#### Resistance evidence

Treatment	Mutation	Evidence source	Evidence level	Found in molecular analysis
FOLFIRI	GENE S11C	[1]	D	Yes

All results and data described in this report are for Research Use Only and have NOT been generated using a clinically validated and controlled procedure nor is it a validated medical device. The results should NOT be used for diagnostic or treatment purposes. No rights can be derived from the content of this report.

# ACTIN Report (research use only)

PATIENT  
EXAMPLE-CRC-01  
  
REPORT DATE  
17-Sep-2025

## Clinical Details

### Clinical summary

Relevant systemic treatment history	<b>None</b>	
Relevant other oncological history	11/2021	<b>Hemicolectomy right (Cecum)</b>
Previous primary tumor	<b>Skin squamous cell carcinoma (diagnosed 6/2016, last treatment 8/2016, considered non-active)</b>	
Relevant non-oncological history	1/2019	<b>Cerebrovascular accident</b>

### Patient current details (05-Mar-2023)

Unresolved toxicities grade => 2	<b>None</b>
Known allergies	<b>Morphine</b>
Recent surgeries	<b>12-Nov-2021 Hemicolectomy right</b>

### Tumor details (05-Mar-2023)

Measurable disease	<b>Yes</b>
Known lesions	<b>Lung, Peritoneal</b>
No lesions present	<b>CNS, Brain, Liver, Bone</b>

### Active medication details

None

### Blood transfusions

Product	Date
ERTHROCYTES_FILTERED	10-Jan-2023

## Trial Matching Details

### Trials and cohorts that are potentially eligible, but are closed (2 cohorts from 1 trial)

Trial	Cohort	Molecular	Sites	Warnings
<a href="#">METC 01 IEMOEN</a>	<i>Applies to all cohorts below</i>	None		Has not exhausted SOC
	Dose escalation - monotherapy			
	Dose expansion - monotherapy			

### Trials and cohorts that are considered ineligible (2 cohorts from 1 trial)

Trial	Cohort	Molecular	Ineligibility reasons
<a href="#">METC 02 KAYRAS</a>	<i>Applies to all cohorts below</i>	KRAS G12D	PD-L1 expression below minimum of 50.0
	Dose expansion - monotherapy - Colorectum		
	Dose expansion - monotherapy - NSCLC		No lung non-small cell carcinoma

### Trials and cohorts that are not evaluable or ignored (0 trials)

None